Table 2 Monoclonal antibodies in clinical trials for the treatment of head and neck cancers
From: A review on the advances and challenges of immunotherapy for head and neck cancer
mAb | Target | Phase | Combined with | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
Bevacizumab | VEGF-A | III | Chemotherapy | NCT00588770 |
Bevacizumab | VEGF-A | I/II | Erlotinib | NCT00055913 |
Ramucirumab | VEGFR2 | I/II | Pembrolizumab | NCT03650764 |
Ficlatuzumab | HGF | II | Cetuximab | NCT03422536 |
Cetuximab | EGFR | II | – | NCT03769311 |
Cetuximab | EGFR | II | Afatinib | NCT02979977 |
Trastuzumab | HER2 | II | – | NCT00004163 |
Panitumumab | EGFR | II | Paclitaxel | NCT01264328 |
Panitumumab | EGFR | I | Chemotherapy | NCT00513383 |
Nivolumab | PD-1 | II | Paclitaxel | NCT04282109 |
Nivolumab | PD-1 | II | Relatlimab/Ipilimumab | NCT04080804 |
Pembrolizumab | PD-1 | I | Clopidogrel/Acetylsalicylic acid | NCT03245489 |
Pembrolizumab | PD-1 | II | Tadalafil | NCT03993353 |
Atezolizumab | PD-L1 | II | Bevacizumab | NCT03818061 |
Durvalumab | PD-L1 | II | Cetuximab | NCT03691714 |
Durvalumab | PD-L1 | II | Carboplatin/Paclitaxel | NCT03723967 |
Ipilimumab | CTLA-4 | I | – | NCT02812524 |
Tremelimumab | CTLA-4 | II | Durvalumab/Radiotherapy | NCT03624231 |